Non-interventional Study With Nab-Paclitaxel (Abraxane®) (NABUCCO)

iOMEDICO logo

iOMEDICO

Status

Completed

Conditions

Metastatic Breast Cancer

Study type

Observational

Funder types

Industry

Identifiers

NCT01689610
IOM-02240

Details and patient eligibility

About

The purpose of this non-interventional study is to collect data on the efficacy and safety of Nab-Paclitaxel in the routine application.

Full description

The main focus of this non-interventional study is set on answering the following questions: Can the results observed in controlled clinical trials regarding efficacy and safety be reproduced in the routine clinical setting? Are the side-effects of nab-paclitaxel therapy observed in this study comparable to the previously described safety-profile in terms of frequency and intensity? What are the main reasons for modification or termination of the nab-paclitaxel therapy? How does nab-paclitaxel therapy influence the patients' quality of life? What are the criteria for selecting nab-paclitaxel as therapy for metastatic breast cancer?

Enrollment

705 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Female Patients with metastatic breast cancer, who are at least 18 years old (no upper age limit)

Exclusion criteria

  • Contraindication according to the summary of product characteristics of Abraxane®
  • No signed patient informed consent form available
  • pregnant or breastfeeding patients.

Trial design

705 participants in 1 patient group

Adult female patients with MBC
Description:
This is an observational study, no interventions are specified

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems